New Qualifying Therapeutic Discovery Project Credit Will Benefit Biotech Companies
The Patient Protection and Affordable Care Act adds a new provision to the Internal Revenue Code that could provide a significant benefit to small and mid-size companies in the biotechnology industry. The Act, which was signed by President Obama on March 23, authorizes the Secretary of the Treasury to award up to $1 billion in qualifying therapeutic discovery project credits in 2009 and 2010. The credit is equal to 50% of an eligible taxpayer’s qualified investment in a qualifying therapeutic discovery project.
Topics
- Rule 14a-11
- Rule 14a-8
- Public Company Transition Rules
- Performance-Based Compensation
- IRS
- Code Section 162(m)
- Corporate Law
- Proxy Access Rules
- Wall Street Reform
- Executive Compensation
- Corporate Governance
- Consumer Protection Act
- Tax Credit
- Qualifying Therapeutic Discovery Project
- Health Care Act
- Corporate Tax
- Employment Incentives
- HIRE Act
- Social Security Tax
- Securities Law
- NYSE Rule 452
Contributors
Subscribe to RSS
Recent Posts
- ISS Announces GRId 2.0 and Publishes 2012 Pay-for-Performance Whitepaper
- S.E.C. Will Not Appeal Decision on Mandatory Proxy Access; Proxy Access on a Company-by-Company Basis Still a Possibility
- D.C. Circuit Vacates Stayed Proxy Access Rule
- IRS Issues Proposed Regulations Under Code Section 162(m)
- SEC Adopts Final Rules on Whistleblower Incentives and Protection
- SEC Proposes Revised Accredited Investor Definition
- Securities and Exchange Commission Adopts Say-on-Pay
- FASB Revises Timeline for Adoption of New Exposure Draft on Disclosure of Certain Loss Contingencies
- SEC Releases Proposed Rules on Say-on-Pay, Say-on-Frequency and Say-on-Parachutes
- Proxy Access on Hold - For Now
Other KMK Blogs
- Complex Litigation
- Corporate & Securities Blog
- Electronic Discovery Road Map
- Management Rights
- Real Estate Blog
- The Cutting Edge of IP
IRS Circular 230 Disclosure: Unless we have specifically stated to the contrary in writing, any discussion of federal tax issues or submissions in this communication (including any attachments) is not intended or written to be used, and cannot be used, for the purpose of (1) avoiding penalties under the United States federal tax laws or (2) promoting, marketing, or recommending to anyone any transaction or matter addressed herein.